scholarly journals Correction: Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological response

Nanoscale ◽  
2021 ◽  
Author(s):  
Jie Yu ◽  
Xidong He ◽  
Zigui Wang ◽  
Yupeng Wang ◽  
Sha Liu ◽  
...  
Keyword(s):  
Cell Death ◽  
Photothermal Therapy ◽  
Immunological Response ◽  
Immunogenic Cell Death ◽  
Thermosensitive Liposome ◽  
Liposome System

Correction for ‘Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological response’ by Jie Yu et al., Nanoscale, 2021, DOI: 10.1039/d1nr03288g.

Combining PD-L1 Inhibitors with Immunogenic Cell Death Triggered by Chemo-Photothermal therapy via a Thermosensitive Liposome System to Stimulate Tumor-specific Immunological Response

Nanoscale ◽  
2021 ◽  
Author(s):  
Jie Yu ◽  
Xidong He ◽  
Zigui Wang ◽  
Yu Peng Wang ◽  
Sha Liu ◽  
...  
Keyword(s):  
Cell Death ◽  
Immune Responses ◽  
Photothermal Therapy ◽  
Immunological Response ◽  
Immune Checkpoint Blockade ◽  
Immunogenic Cell Death ◽  
Adaptive Immune Responses ◽  
Adaptive Immune ◽  
Thermosensitive Liposome ◽  
Liposome System

Immune checkpoint blockade (ICB) therapy in combination with immunogenic death (ICD) triggered by photothermal therapy (PTT) and oxaliplatin (OXA) treatment was expected to elicit both innate and adaptive immune responses...

Induction of Immunogenic Cell Death in Breast Cancer by Conductive Polymer Nanoparticle-Mediated Photothermal Therapy

2020 ◽  
Vol 2 (12) ◽  
pp. 5602-5620
Author(s):  
Madeline Elaine Huff ◽  
Fatma Özge Gökmen ◽  
Jessica S. Barrera ◽  
Emilio J. Lara ◽  
James Tunnell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Death ◽  
Photothermal Therapy ◽  
Conductive Polymer ◽  
Immunogenic Cell Death ◽  
Polymer Nanoparticle

Induction of immunogenic cell death of cancer cells through nanoparticle-mediated dual chemotherapy and photothermal therapy

2020 ◽  
Vol 589 ◽  
pp. 119787 ◽  
Author(s):  
Niloofar Heshmati Aghda ◽  
Shahad M. Abdulsahib ◽  
Carli Severson ◽  
Emilio J. Lara ◽  
Susana Torres Hurtado ◽  
...  
Keyword(s):  
Cell Death ◽  
Cancer Cells ◽  
Photothermal Therapy ◽  
Immunogenic Cell Death

Photothermal therapy-induced immunogenic cell death based on natural melanin nanoparticles against breast cancer

2020 ◽  
Vol 56 (9) ◽  
pp. 1389-1392 ◽  
Author(s):  
Yanhua Li ◽  
Xiaohan Liu ◽  
Wei Pan ◽  
Na Li ◽  
Bo Tang
Keyword(s):  
Breast Cancer ◽  
Cell Death ◽  
Photothermal Therapy ◽  
Immunogenic Cell Death ◽  
Breast Cancers ◽  
Therapy Strategy ◽  
Melanin Nanoparticles

A photothermal and immune co-therapy strategy based on natural melanin nanoparticles was developed for treating primary and abscopal breast cancers.

Photothermal Therapy Generates a Thermal Window of Immunogenic Cell Death in Neuroblastoma

Small ◽  
2018 ◽  
Vol 14 (20) ◽  
pp. 1800678 ◽  
Author(s):  
Elizabeth E. Sweeney ◽  
Juliana Cano-Mejia ◽  
Rohan Fernandes
Keyword(s):  
Cell Death ◽  
Photothermal Therapy ◽  
Immunogenic Cell Death ◽  
Thermal Window

scholarly journals Chemo-photothermal Therapy Promoting Immunogenic Cell Death Based on NIR-II Light-responsive Drug Delivery Systems

2021 ◽  
Author(s):  
Lifeng Hang ◽  
Wuming Li ◽  
Dandan Men ◽  
Hua Wen ◽  
Xinfeng Tang ◽  
...  
Keyword(s):  
Cell Death ◽  
T Lymphocytes ◽  
Cytotoxic T Lymphocytes ◽  
Photothermal Therapy ◽  
Drug Loading ◽  
Hollow Structure ◽  
Photothermal Effect ◽  
Great Promise ◽  
Immunogenic Cell Death ◽  
Single Treatment

Abstract Background Several recent studies have well demonstrated that the chemotherapy or near-infrared-II (NIR-II) photothermal therapy (PTT) can induce immunogenic cell death (ICD). However, single treatment based on the independent chemotherapy or PTT to induce ICD may require high dose of drug, high laser power, or high temperature, which limits their clinical application. We hypothesize that combination of chemotherapy and NIR-II PTT possesses great promise to overcome respective limitations. This manuscript describes the development of polyethylene glycol (PEG) modified hollow CuxS nanoparticles (NPs) for synergistic chemo-photothermal therapy to effectively promote ICD.Results Hollow structure CuxS-PEG NPs were prepared under mild condition by using Cu2O NPs as sacrificial templates. CuxS loaded with doxorubicin (Dox) as NDDSs were characterized for hydrate particle size and surface charge. The morphology, photothermal effect, drug loading/releasing abilities, synergistic chemo-photothermal therapy, and ICD from synergistic therapy of CuxS-PEG NPs have been investigated. The in vitro outcomes of ICD and chemo-photothermal therapy were assessed in EMT-6 cells. In vivo therapeutic studies and immunoreaction were performed in EMT-6 bearing mice where therapeutic outcomes were assessed by tumor volume, immunohistochemical staining, and expression of CD8+ cytotoxic T-lymphocytes. The CuxS-PEG NPs with hollow structure show high drug loading capacity (~255 μg Dox per mg of CuxS NPs) and stimuli-responsive drug release triggered by NIR-II laser irradiation. The chemo-photothermal strategy more effectively induces ICD than that of the single treatment, accompanying with the release of adenosine triphosphate, pre-apoptotic calreticulin, and high mobility group box-1. Finally, the synergistic chemo-photothermal therapy based on the Dox/CuxS-PEG NPs promotes CD8+ cytotoxic T-lymphocytes infiltration into tumors and achieves ~98.5% tumor elimination.Conclusion Therefore, our study emphasizes that the great potentials of CuxS-PEG NPs can be used as NIR-II light-responsive NDDSs for the applications of biomedicine and immunotherapy.

Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine

Planta Medica ◽  
2012 ◽  
Vol 78 (11) ◽  
Author(s):  
HM Chen ◽  
PH Wang ◽  
SS Chen ◽  
CC Wen ◽  
YH Chen ◽  
...  
Keyword(s):  
Cell Death ◽  
Dendritic Cell ◽  
Tumor Cells ◽  
Cancer Vaccine ◽  
Immunogenic Cell Death

Phototherapy and anti-GITR antibody-based therapy synergistically reinvigorate immunogenic cell death and reject established cancers

Biomaterials ◽  
2021 ◽  
pp. 120648
Author(s):  
Qi Sun ◽  
Zhenzhen Yang ◽  
Meng Lin ◽  
Yiwei Peng ◽  
Rudong Wang ◽  
...  
Keyword(s):  
Cell Death ◽  
Immunogenic Cell Death

scholarly journals Damage-Associated Molecular Patterns Modulation by microRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2566
Author(s):  
María Julia Lamberti ◽  
Annunziata Nigro ◽  
Vincenzo Casolaro ◽  
Natalia Belén Rumie Vittar ◽  
Jessica Dal Col
Keyword(s):  
Cell Death ◽  
Tumor Cells ◽  
Cell Activation ◽  
Adaptive Immune Response ◽  
Current Status ◽  
Immunogenic Cell Death ◽  
Basal Expression ◽  
Antigen Presenting ◽  
Molecular Patterns ◽  
Damage Associated Molecular Patterns

Immunogenic cell death (ICD) in cancer is a functionally unique regulated form of stress-mediated cell death that activates both the innate and adaptive immune response against tumor cells. ICD makes dying cancer cells immunogenic by improving both antigenicity and adjuvanticity. The latter relies on the spatiotemporally coordinated release or exposure of danger signals (DAMPs) that drive robust antigen-presenting cell activation. The expression of DAMPs is often constitutive in tumor cells, but it is the initiating stressor, called ICD-inducer, which finally triggers the intracellular response that determines the kinetics and intensity of their release. However, the contribution of cell-autonomous features, such as the epigenetic background, to the development of ICD has not been addressed in sufficient depth. In this context, it has been revealed that several microRNAs (miRNAs), besides acting as tumor promoters or suppressors, can control the ICD-associated exposure of some DAMPs and their basal expression in cancer. Here, we provide a general overview of the dysregulation of cancer-associated miRNAs whose targets are DAMPs, through which new molecular mediators that underlie the immunogenicity of ICD were identified. The current status of miRNA-targeted therapeutics combined with ICD inducers is discussed. A solid comprehension of these processes will provide a framework to evaluate miRNA targets for cancer immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document